Blinatumomab for MRD 1 B-all: The evidence strengthens

Research output: Contribution to journalReview articlepeer-review

Abstract

In this issue of Blood, Gökbuget et al provide strong evidence that immunotherapy with blinatumomab can eliminate residual chemotherapy-resistant B-cell acute lymphoblastic leukemia (B-ALL) cells and that this prevents subsequent relapse and improves survival. 1 This addresses the most important unsolved clinical problem in adults with B-ALL: the development of chemotherapy-resistant relapsed disease.

Original languageEnglish (US)
Pages (from-to)1497-1498
Number of pages2
JournalBlood
Volume131
Issue number14
DOIs
StatePublished - Apr 5 2018

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Blinatumomab for MRD <sup>1</sup> B-all: The evidence strengthens'. Together they form a unique fingerprint.

Cite this